세계의 항체 치료 시장 규모 조사 : 형식별, 투여 경로별, 유래별, 질환 영역별, 최종 사용자별, 지역별 예측(2022-2032년)

Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2022-2032

US $ 4,950 ￦ 7,162,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 6,250 ￦ 9,043,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항체 치료 시장은 2023년 약 2,487억 9,000만 달러로 평가되었고, 2024-2032년의 예측 기간 동안 14.89% 이상의 견조한 성장률을 나타낼 것으로 예상됩니다.

항체 치료는 항체를 활용하여 면역체계가 질병과 싸우는 능력을 강화하거나 모방하는 치료법 중 하나입니다. 항체 치료는 기존 약물에 비해 특이성이 높고 독성이 낮기 때문에 암, 자가면역질환, 감염성 질환 등 다양한 질병에 대한 효과적인 치료법으로 부상하고 있습니다. 만성질환의 확산과 전 세계 의료비 증가는 항체 의약품의 채택을 크게 촉진하고 있습니다. 이러한 어려움에도 불구하고 의료기술의 발전은 보다 효율적인 항체 생산으로 이어지고 있으며, 차세대 항체의 출현과 암 치료에 대한 정부의 지원책은 시장 성장에 큰 기회를 제공할 것으로 예상됩니다.

시장 역학은 많은 규제 당국의 승인으로 단클론항체의 사용이 크게 증가하고 있으며, 더 나은 종양 침투와 면역원성 감소를 위해 항체 조각의 사용이 확대되고 있습니다. 이중 친화력을 가진 이중 특이성 항체도 암 치료에서 다양한 용도로 활용되고 있습니다. 한편, 피하투여는 자가투여의 편의성과 비용 효율성이 높습니다. 그러나 높은 개발 비용과 복잡한 승인 절차 등의 문제로 인해 2024년부터 2032년까지 시장 성장이 둔화될 것으로 예상됩니다.

지역별 분석은 북미, 유럽, 아시아태평양, 라틴아메리카 및 기타 세계 주요 지역을 대상으로 합니다. 북미는 잘 구축된 R&D 생태계와 높은 의료비 지출로 시장을 선도하고 있습니다. 북미, 특히 미국은 연구개발(R&D)에 집중하고 있으며, 고도로 발달된 의료 시스템을 자랑합니다. 이러한 인프라는 대규모 임상시험을 지원하고 새로운 치료법의 신속한 도입을 촉진하고 있습니다. 북미에는 Amgen, Genentech(Roche의 자회사), Johnson & Johnson 등 다양한 대형 제약 및 생명공학 기업이 있습니다. 이들 기업은 항체 치료 개발 및 상용화에 많은 투자를 하고 있습니다. 또한, 아시아태평양은 의료 인프라의 성장과 만성질환 유병률 증가로 인해 가장 빠른 성장세를 보일 것으로 예상됩니다. 또한, 강력한 제약 산업과 종합적인 지적재산권 프레임워크를 갖춘 유럽연합(EU)도 항체치료제 환경에서 매우 중요한 역할을 하고 있습니다.

목차

제1장 세계의 항체 치료 시장 주요 요약

• 세계의 항체 치료 시장 규모와 예측(2022년-2032년)
• 지역별 개요
• 부문별 개요
  • 포맷별
  • 투여 경로별
  • 유래별
  • 질환 영역별
  • 최종사용자별
• 주요 동향
• 불황의 영향
• 애널리스트의 결론 및 제안

제2장 세계의 항체 치료 시장 정의와 조사의 전제조건

• 조사 목적
• 시장의 정의
• 조사의 전제조건
  • 포함과 제외
  • 제한 사항
  • 공급측 분석
    • 가용성
    • 인프라
    • 규제 환경
    • 시장 경쟁
    • 경제성(소비자 시점)
  • 수요측 분석
    • 규제 프레임워크
    • 기술 진보
    • 친환경
    • 소비자 의식과 수용
• 조사 방법
• 조사 대상년도
• 통화 환산율

제3장 세계의 항체 치료 시장 역학

• 시장 성장 촉진요인 ]
• 시장이 해결해야 할 과제
• 시장 기회

  제4장 세계의 항체 치료 시장 산업 분석

  • Porter's Five Forces 모델
    • 공급 기업의 교섭력
    • 바이어의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계
    • Porter's Five Forces 모델에 대한 미래적 접근
    • Porter's Five Forces의 영향 분석
  • PESTEL 분석
    • 정치
    • 경제
    • 사회
    • 기술
    • 환경
    • 법률
  • 주요 투자 기회
  • 주요 성공 전략
  • 파괴적 동향
  • 업계 전문가의 견해
  • 애널리스트의 결론 및 제안

  제5장 세계의 항체 치료 시장 규모와 예측 : 포맷별, 2022년-2032년

  • 부문 대시보드
  • 세계의 항체 치료 시장 : 매출 동향 분석, 2022년·2032년
    • 항체 프래그먼트
    • 이중특이성항체
    • 단클론항체
    • 다중클론항체

  제6장 세계의 항체 치료 시장 규모와 예측 : 투여 경로별, 2022년-2032년

  • 부문 대시보드
  • 세계의 항체 치료 시장 : 매출 동향 분석, 2022년·2032년
    • 정맥내 투여
    • 피하 투여

  제7장 세계의 항체 치료 시장 규모와 예측 : 유래별, 2022년-2032년

  • 부문 대시보드
  • 세계의 항체 치료 시장 : 매출 동향 분석, 2022년·2032년
    • 키메라
    • 인간
    • 인간화 항체

  제8장 세계의 항체 치료 시장 규모와 예측 : 질환 영역별, 2022년-2032년

  • 부문 대시보드
  • 세계의 항체 치료 시장 : 매출 동향 분석, 2022년·2032년
    • 자가면역 질환 및 염증성 질환
    • 혈액학
    • 면역학
    • 신경학
    • 종양학
    • 뼈과학

  제9장 세계의 항체 치료 시장 규모와 예측 : 최종사용자별, 2022년-2032년

  • 부문 대시보드
  • 세계의 항체 치료 시장 : 매출 동향 분석, 2022년·2032년
    • 병원
    • 장기요양 시설

  제10장 세계의 항체 치료 시장 규모와 예측 : 지역별, 2022년-2032년

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 사우디아라비아
    • 남아프리카공화국
    • 기타 중동 및 아프리카

  제11장 경쟁 정보

  • 주요 기업의 SWOT 분석
    • AbbVie Inc.
    • AbCellera Biologics Inc.
    • Adaptimmune Therapeutics PLC.
  • 주요 시장 전략
  • 기업 개요
    • AbbVie Inc.
      • 주요 정보
      • 개요
      • 재무 정보(데이터 입수가 가능한 경우)
      • 제품 개요
      • 시장 전략
    • AbCellera Biologics Inc.
    • Adaptimmune Therapeutics PLC.
    • ADC Therapeutics SA
    • Aenova Holding GmbH
    • Almac Group Limited
    • Amgen Inc.
    • Antikor Biopharma
    • Argenx SE
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.

  제12장 조사 과정

  • 조사 과정
    • 데이터 마이닝
    • 분석
    • 시장 추정
    • 검증
    • 출판
  • 조사 속성
  LSH

영문 목차

영문목차

The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system's ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.

The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.

Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.

Major market players included in this report are:

• AbbVie Inc.
• AbCellera Biologics Inc.
• Adaptimmune Therapeutics PLC
• ADC Therapeutics SA
• Aenova Holding GmbH
• Almac Group Limited
• Amgen Inc.
• Antikor Biopharma
• Argenx SE
• Astellas Pharma Inc.
• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.

The detailed segments and sub-segment of the market are explained below:

By Format:

• Antibody Fragment
• Bispecific Antibody
• Monoclonal Antibody
• Polyclonal Antibody

By Route of Administration:

• Intravenous
• Subcutaneous

By Source:

• Chimeric
• Human
• Humanized

By Disease Areas:

• Autoimmune & Inflammatory Diseases
• Hematology
• Immunology
• Neurology
• Oncology
• Osteology

By End User:

• Hospitals
• Long-term Care Facilities

By Region:

North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific:

• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America:

• Brazil
• Mexico

Middle East & Africa:

• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Antibody Therapeutics Market Executive Summary

• 1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Format
  • 1.3.2. By Route of Administration
  • 1.3.3. By Source
  • 1.3.4. By Disease Areas
  • 1.3.5. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antibody Therapeutics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Antibody Therapeutics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Prevalence of Chronic Diseases
  • 3.1.2. Advancements in Medical Technology
• 3.2. Market Challenges
  • 3.2.1. High Development Costs
  • 3.2.2. Complex Regulatory Approvals
• 3.3. Market Opportunities
  • 3.3.1. Emergence of Next-Generation Antibodies
  • 3.3.2. Supportive Government Initiatives for Cancer Care

Chapter 4. Global Antibody Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antibody Therapeutics Market Size & Forecasts by Format 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Antibody Fragment
  • 5.2.2. Bispecific Antibody
  • 5.2.3. Monoclonal Antibody
  • 5.2.4. Polyclonal Antibody

Chapter 6. Global Antibody Therapeutics Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Intravenous
  • 6.2.2. Subcutaneous

Chapter 7. Global Antibody Therapeutics Market Size & Forecasts by Source 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Chimeric
  • 7.2.2. Human
  • 7.2.3. Humanized

Chapter 8. Global Antibody Therapeutics Market Size & Forecasts by Disease Areas 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Autoimmune & Inflammatory Diseases
  • 8.2.2. Hematology
  • 8.2.3. Immunology
  • 8.2.4. Neurology
  • 8.2.5. Oncology
  • 8.2.6. Osteology

Chapter 9. Global Antibody Therapeutics Market Size & Forecasts by End User 2022-2032

• 9.1. Segment Dashboard
• 9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 9.2.1. Hospitals
  • 9.2.2. Long-term Care Facilities

Chapter 10. Global Antibody Therapeutics Market Size & Forecasts by Region 2022-2032

• 10.1. North America Antibody Therapeutics Market
  • 10.1.1. U.S. Antibody Therapeutics Market
    • 10.1.1.1. Format breakdown size & forecasts, 2022-2032
    • 10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.1.1.3. Source breakdown size & forecasts, 2022-2032
    • 10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.1.1.5. End User breakdown size & forecasts, 2022-2032
  • 10.1.2. Canada Antibody Therapeutics Market
    • 10.1.2.1. Format breakdown size & forecasts, 2022-2032
    • 10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.1.2.3. Source breakdown size & forecasts, 2022-2032
    • 10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.1.2.5. End User breakdown size & forecasts, 2022-2032
• 10.2. Europe Antibody Therapeutics Market
  • 10.2.1. UK Antibody Therapeutics Market
    • 10.2.1.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.1.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.1.5. End User breakdown size & forecasts, 2022-2032
  • 10.2.2. Germany Antibody Therapeutics Market
    • 10.2.2.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.2.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.2.5. End User breakdown size & forecasts, 2022-2032
  • 10.2.3. France Antibody Therapeutics Market
    • 10.2.3.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.3.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.3.5. End User breakdown size & forecasts, 2022-2032
  • 10.2.4. Spain Antibody Therapeutics Market
    • 10.2.4.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.4.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.4.5. End User breakdown size & forecasts, 2022-2032
  • 10.2.5. Italy Antibody Therapeutics Market
    • 10.2.5.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.5.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.5.5. End User breakdown size & forecasts, 2022-2032
  • 10.2.6. Rest of Europe Antibody Therapeutics Market
    • 10.2.6.1. Format breakdown size & forecasts, 2022-2032
    • 10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.2.6.3. Source breakdown size & forecasts, 2022-2032
    • 10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.2.6.5. End User breakdown size & forecasts, 2022-2032
• 10.3. Asia-Pacific Antibody Therapeutics Market
  • 10.3.1. China Antibody Therapeutics Market
    • 10.3.1.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.1.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.1.5. End User breakdown size & forecasts, 2022-2032
  • 10.3.2. India Antibody Therapeutics Market
    • 10.3.2.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.2.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.2.5. End User breakdown size & forecasts, 2022-2032
  • 10.3.3. Japan Antibody Therapeutics Market
    • 10.3.3.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.3.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.3.5. End User breakdown size & forecasts, 2022-2032
  • 10.3.4. Australia Antibody Therapeutics Market
    • 10.3.4.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.4.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.4.5. End User breakdown size & forecasts, 2022-2032
  • 10.3.5. South Korea Antibody Therapeutics Market
    • 10.3.5.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.5.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.5.5. End User breakdown size & forecasts, 2022-2032
  • 10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
    • 10.3.6.1. Format breakdown size & forecasts, 2022-2032
    • 10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.3.6.3. Source breakdown size & forecasts, 2022-2032
    • 10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.3.6.5. End User breakdown size & forecasts, 2022-2032
• 10.4. Latin America Antibody Therapeutics Market
  • 10.4.1. Brazil Antibody Therapeutics Market
    • 10.4.1.1. Format breakdown size & forecasts, 2022-2032
    • 10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.4.1.3. Source breakdown size & forecasts, 2022-2032
    • 10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.4.1.5. End User breakdown size & forecasts, 2022-2032
  • 10.4.2. Mexico Antibody Therapeutics Market
    • 10.4.2.1. Format breakdown size & forecasts, 2022-2032
    • 10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.4.2.3. Source breakdown size & forecasts, 2022-2032
    • 10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.4.2.5. End User breakdown size & forecasts, 2022-2032
  • 10.4.3. Rest of Latin America Antibody Therapeutics Market
    • 10.4.3.1. Format breakdown size & forecasts, 2022-2032
    • 10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.4.3.3. Source breakdown size & forecasts, 2022-2032
    • 10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.4.3.5. End User breakdown size & forecasts, 2022-2032
• 10.5. Middle East & Africa Antibody Therapeutics Market
  • 10.5.1. Saudi Arabia Antibody Therapeutics Market
    • 10.5.1.1. Format breakdown size & forecasts, 2022-2032
    • 10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.5.1.3. Source breakdown size & forecasts, 2022-2032
    • 10.5.1.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.5.1.5. End User breakdown size & forecasts, 2022-2032
  • 10.5.2. South Africa Antibody Therapeutics Market
    • 10.5.2.1. Format breakdown size & forecasts, 2022-2032
    • 10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.5.2.3. Source breakdown size & forecasts, 2022-2032
    • 10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.5.2.5. End User breakdown size & forecasts, 2022-2032
  • 10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
    • 10.5.3.1. Format breakdown size & forecasts, 2022-2032
    • 10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.5.3.3. Source breakdown size & forecasts, 2022-2032
    • 10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
    • 10.5.3.5. End User breakdown size & forecasts, 2022-2032

Chapter 11. Competitive Intelligence

• 11.1. Key Company SWOT Analysis
  • 11.1.1. AbbVie Inc.
  • 11.1.2. AbCellera Biologics Inc.
  • 11.1.3. Adaptimmune Therapeutics PLC.
• 11.2. Top Market Strategies
• 11.3. Company Profiles
  • 11.3.1. AbbVie Inc.
    • 11.3.1.1. Key Information
    • 11.3.1.2. Overview
    • 11.3.1.3. Financial (Subject to Data Availability)
    • 11.3.1.4. Product Summary
    • 11.3.1.5. Market Strategies
  • 11.3.2. AbCellera Biologics Inc.
  • 11.3.3. Adaptimmune Therapeutics PLC.
  • 11.3.4. ADC Therapeutics SA
  • 11.3.5. Aenova Holding GmbH
  • 11.3.6. Almac Group Limited
  • 11.3.7. Amgen Inc.
  • 11.3.8. Antikor Biopharma
  • 11.3.9. Argenx SE
  • 11.3.10. Astellas Pharma Inc.
  • 11.3.11. AstraZeneca PLC
  • 11.3.12. Baxter International Inc.
  • 11.3.13. Bayer AG
  • 11.3.14. Becton, Dickinson and Company
  • 11.3.15. Bio-Rad Laboratories, Inc.

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes

관련자료